dc.contributor.author | Vickers, AJ | |
dc.contributor.author | Sud, A | |
dc.contributor.author | Bernstein, J | |
dc.contributor.author | Houlston, R | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-06-22T10:18:37Z | |
dc.date.available | 2022-06-22T10:18:37Z | |
dc.date.issued | 2022-05-30 | |
dc.identifier | ARTN 32 | |
dc.identifier | 10.1038/s41698-022-00280-w | |
dc.identifier.citation | npj Precision Oncology, 2022, 6 (1), pp. 32 - | en_US |
dc.identifier.issn | 2397-768X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5186 | |
dc.identifier.eissn | 2397-768X | |
dc.identifier.eissn | 2397-768X | |
dc.identifier.doi | 10.1038/s41698-022-00280-w | |
dc.description.abstract | Population-based cancer screening programs such as mammography or colonscopy generally directed at all healthy individuals in a given age stratum. It has recently been proposed that cancer screening could be restricted to a high-risk subgroup based on polygenic risk scores (PRSs) using panels of single-nucleotide polymorphisms (SNPs). These PRSs were, however, generated to predict cancer incidence rather than cancer mortality and will not necessarily address overdiagnosis, a major problem associated with cancer screening programs. We develop a simple net-benefit framework for evaluating screening approaches that incorporates overdiagnosis. We use this methodology to demonstrate that if a PRS does not differentially discriminate between incident and lethal cancer, restricting screening to a subgroup with high scores will only improve screening outcomes in a small number of scenarios. In contrast, restricting screening to a subgroup defined as high-risk based on a marker that is more strongly predictive of mortality than incidence will often afford greater net benefit than screening all eligible individuals. If PRS-based cancer screening is to be effective, research needs to focus on identifying PRSs associated with cancer mortality, an unchartered and clinically-relevant area of research, with a much higher potential to improve screening outcomes. | |
dc.format | Electronic | |
dc.format.extent | 32 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | NATURE PORTFOLIO | en_US |
dc.relation.ispartof | npj Precision Oncology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Oncology | |
dc.subject | LUNG-CANCER | |
dc.subject | OVERDIAGNOSIS | |
dc.title | Polygenic risk scores to stratify cancer screening should predict mortality not incidence. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-04-15 | |
dc.date.updated | 2022-06-21T19:47:23Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1038/s41698-022-00280-w | en_US |
rioxxterms.licenseref.startdate | 2022-05-30 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35637246 | |
pubs.issue | 1 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/14/15 Starting Cohort | |
pubs.publication-status | Published online | |
pubs.volume | 6 | |
icr.researchteam | Cancer Genomics | en_US |
dc.contributor.icrauthor | Sud, Amit | |
dc.contributor.icrauthor | Houlston, Richard | |